Abstract: The present disclosure provides a sensor for tires capable of measuring a physical quantity including a temperature of a tire. An aspect of the present disclosure is a sensor for tires including: a base portion 5 fixed to an inside of a tire T and in contact with the tire T, and a sensor chip 7 including a tire temperature detection unit that detects the temperature of the tire T through the base portion 5.

Abstract: A semiconductor device includes a semiconductor chip, a circuit board, a heat releasing plate, an adhesive member, and a conductive member. The circuit board transmits a signal of the semiconductor chip. The heat releasing plate has the semiconductor chip disposed thereon, and has an opening in a region on the outer side of a semiconductor chip placement region that is a region in which the semiconductor chip is disposed. The adhesive member is disposed in a region on the outer side of the opening on a different surface of the heat releasing plate from the surface on which the semiconductor chip is disposed, and bonds the circuit board and the heat releasing plate to each other. The conductive member connects the semiconductor chip and the circuit board to each other via the opening.

Abstract: An object of the present invention is to provide a strain amount detection device capable of accurately detecting deformations, in multiple directions, of a tire by one strain measuring element. A strain amount detection device according to the present invention includes a disk-shaped base member that holds a strain measuring element, in which the base member acts as a strain body by transmitting strain of a tire to the strain measuring element.

Abstract: The present invention provides: an MRI contrast agent for detecting cartilage damage, which comprises 17O-labeled water; and a method and a program for detecting cartilage damage using the contrast agent. According to the present invention, it becomes possible to detect a damage in a cartilage, particularly a minor damage in the surface layer of a cartilage which has been difficult to detect so far, by using 17O-labeled water as a contrast agent.

Abstract: An object of the present technology is to provide a sample preparation system for increasing the content percentage of target cells. The present technology provides a sample preparation system including a bioparticle-capturing module including a substrate to which a substance that captures bioparticles is fixed, a reservoir into which the bioparticles released from the substrate are recovered, and a hollow fiber membrane module through which the bioparticles in the reservoir are flowed. The present technology also provides a sample preparation method including a capturing step of capturing bioparticles with use of a substrate to which a substance that captures the bioparticles is fixed, a recovery step of recovering, into a reservoir, the bioparticles released from the substrate, and a hollow fiber membrane treatment step of causing the bioparticles recovered into the reservoir to flow through a hollow fiber membrane module.

Abstract: A tip device (1) includes a tubular tip (6) and a base (8) that is continuous with a rear end (6a) of the tip (6) and includes a first connector. The first connector detachably connects to a second connector provided in a container (2) to house the tip (6).

Abstract: To provide a technology for confirming that a desired particle is recovered in single cell analysis. The present technology provides a particle confirming method including a correlating step of correlating ID information possessed by a particle trapped in a well in a particle trapping region with position information of the well, a discharging step of discharging the particle from the well, an ID information acquiring step of acquiring ID information of the particle after the discharging step, and a confirming step of confirming the position of the well in which the particle has been trapped, on the basis of the acquired ID information. In addition, the present technology also provides a particle trapping chip and a particle analyzing system to be used for carrying out the method.

Abstract: To provide a method for detecting a target substance by using an interaction through a molecular species having low reactivity, with two types of microparticles as proximity probes. A target substance detection method includes the following steps of: a step (A) of bringing a biological sample into contact with an oxygen sensor bound to a first molecule that specifically binds to a target substance; a step (B) of bringing the biological sample into contact with a first solid phase support that holds a second molecule and an oxygen-consuming enzyme, the second molecule specifically binding to the target substance; and a step (C) of acquiring information generated from the oxygen sensor by the steps (A) and (B).

Abstract: There is provided a microfluidic device for capturing particles comprising a particle capturing chamber (100) including at least: a particle capturing unit (101) including one of at least one well (106) or at least one through hole (108); and a particle capturing channel unit (102) used for capturing a particle in the well or with the through hole, in which the particle is captured in the well or with the through hole by being sucked, via the particle capturing channel unit, in a direction opposite to a direction (114) on which the particle settles. Such a configuration has for result that the particles that are not captured in the well or with the through hole are prevented from staying in the vicinity of the well or the through hole of the particle capturing unit when suction is stopped.

Abstract: Provided is a hard sintered body which exhibits excellent high temperature oxidation resistance and has a high hardness at a high temperature. In the hard sintered body, a binder phase is contained at from 8.8 to 34.4 mol % and the balance is composed of a hard phase and inevitable impurities. The binder phase contains iron aluminide containing FeAl as a main component and alumina that is dispersed in iron aluminide and has a particle size of 1 ?m or less. The hard phase is composed of at least one kind selected from carbides, nitrides, carbonitrides and borides of Group 4 metals, Group 5 metals and Group 6 metals in the periodic table, and solid solutions of these.

Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is a hard sintered body which exhibits excellent high temperature oxidation resistance and has a high hardness at a high temperature. In the hard sintered body, a binder phase is contained at from 8.8 to 34.4 mol % and the balance is composed of a hard phase and inevitable impurities. The binder phase contains iron aluminide containing FeAl as a main component and alumina that is dispersed in iron aluminide and has a particle size of 1 ?m or less. The hard phase is composed of at least one kind selected from carbides, nitrides, carbonitrides and borides of Group 4 metals, Group 5 metals and Group 6 metals in the periodic table, and solid solutions of these.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.

Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n-NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group. The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.